Rigel Pharmaceuticals has announced the enrolment of the first subject in a Phase Ib/II clinical trial of REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax for patients with ...

The company is also making good progress with its second FDA-approved product, Rezlidhia (olutasidenib). The drug is indicated for the treatment of adult patients with relapsed or refractory (R/R ...

Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 ...

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their ...

TAVALISSE Net Product Sales for Q4 2024: $31 million, a 21% increase year over year. REZLIDHIA Net Product Sales for Q4 2024: $7.4 million, a 92% increase year over year. GAVRETO Net Product Sales ...